Mr. Ken d'Entremont reports

HARMONY P. GARGES MD MPH AND MENASSIE TADDESE MBA APPOINTED TO MEDEXUS'S BOARD OF DIRECTORS; APPOINTMENTS BOLSTER MEDEXUS BOARD'S MEDICAL AND FINANCIAL EXPERTISE, PARTICULARLY IN THE UNITED STATES

Medexus Pharmaceuticals Inc. is pleased to welcome Harmony P. Garges MD, MPH, chief medical officer of ViiV Healthcare, and Menassie Taddese MBA, a former executive at Pfizer and Viatris, to the Medexus board of directors.

"We are very pleased to welcome Harmony and Menassie, two experienced professionals whose skills, experience and expertise will serve to diversify and supplement those of the current members of our board," commented Benoit Gravel, chair of the compensation, corporate governance and nominating committee of the board of directors.

Ken d'Entremont, chief executive officer of Medexus, added: "We are thrilled to have Harmony and Menassie join our board. As we continue to evaluate new opportunities to grow our business, strengthening our team remains a priority. Harmony's significant experience leading medical affairs and medical regulatory matters and Menassie's strong management experience and expertise in corporate finance will undoubtedly be assets as we grow our business organically and engage in new business and corporate development initiatives."

Dr. Garges and Mr. Taddese were elected to fill two newly created directorships with effect as of Feb. 6, 2023, and will initially serve until the next annual meeting of Medexus shareholders. For more information about the Medexus board of directors, see the governance section of Medexus's corporate website.

About Dr. Garges and Mr. Taddese

Dr. Garges brings 18 years of multinational pharmaceutical leadership experience in the United States and the United Kingdom to the Medexus board. Dr. Garges has served as chief medical officer of ViiV Healthcare since August, 2019. In this role, Dr. Garges is accountable for all aspects of human safety and medical governance and for the global medical affairs strategy and execution for the company. Dr. Garges joined ViiV Healthcare in 2016 after spending over a decade at GSK in various leadership roles across research and development, pharmacovigilance and medical affairs. During her career, Dr. Garges has provided medical leadership for over a dozen new drug applications and new product launches.

Mr. Taddese is a seasoned veteran of the biopharmaceutical industry with wide-ranging experience in general management, finance, business transformation, partnership creation and overall leadership. He brings over 26 years of experience leading large commercial and cross-functional organizations across the globe to the Medexus board.

About Medexus Pharmaceuticals Inc.

Medexus is a leader in innovative and rare disease treatment solutions with a strong North American commercial platform and a portfolio of proven best-in-class products. The company's current focus is on the therapeutic areas of hematology, autoimmune diseases and allergy. The company continues to build a highly differentiated company with a growing portfolio of innovative and high-value orphan and rare disease products which will underpin the company's growth for the next decade. The company's current leading products are Ixinity, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B (a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding); Rasuvo and Metoject, a unique formulation of methotrexate (auto-pen and prefilled syringe) designed to treat rheumatoid arthritis and other autoimmune diseases; Rupall, an innovative prescription allergy medication with a unique mode of action; and Gleolan (aminolevulinic acid hydrochloride or ALA HCl), a U.S. Food and Drug Administration-approved, orphan-drug-designated optical imaging agent currently indicated in patients with glioma (suspected World Health Organization Grade 3 or Grade 4 on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. The company has also licensed treosulfan, part of a preparative regimen for allogeneic hematopoietic stem cell transplantation to be used in combination with fludarabine, for commercialization in the United States and Canada. Treosulfan was approved by Health Canada in June, 2021, and is marketed in Canada as Trecondyv. Treosulfan is currently the subject of a regulatory review process with the U.S. Food and Drug Administration. The company's mission is to provide the best health care products to health care professionals and patients. The company strives to deliver on this mission by acting on its core values: quality, innovation, customer service and collaboration.

We seek Safe Harbor.